CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

A method of treating a subject having a hematological cancer, comprising administering to the subject an effective number of:

• one or more cells that express a CAR molecule that binds CD19 in combination with one or more cells that express a CAR molecule that binds CD22, wherein:
• (a) the CD22 CAR molecule comprises a CD22 binding domain comprising a light chain complementary determining region 1 (LC CDR1) of SEQ ID NO:
• 648, a light chain complementary determining region 2 (LC CDR2) of SEQ ID NO:
• 659, and a light chain complementary determining region 3 (LC CDR3) of SEQ ID NO:
• 670, and a heavy chain complementary determining region 1 (HC CDR1) of SEQ ID NO:
• 498 or SEQ ID NO:
• 1345, a heavy chain complementary determining region 2 (HC CDR2) of SEQ ID NO:509 or SEQ ID NO:
• 1354, and a heavy chain complementary determining region 3 (HC CDR3) of SEQ ID NO:
• 520 or SEQ ID NO:
• 1363;
• and
• (b) the CD19 CAR molecule comprises a CD19 binding domain comprising:
• (i) a LC CDR1 of SEQ ID NO:
• 25, a LC CDR2 of SEQ ID NO:
• 26 and a LC CDR3 of SEQ ID NO:
• 27;
• and a HC CDR1 of SEQ ID NO:
• 19;
• a HC CDR2 of SEQ ID NO:
• 20 and a HC CDR3 of SEQ ID NO:
• 24;
• or
• (ii) a LC CDR1 of SEQ ID NO:
• 25, a LC CDR2 of SEQ ID NO:
• 26 and a LC CDR3 of SEQ ID NO:
• 27;
• and a HC CDR1 of SEQ ID NO:
• 19;
• a HC CDR2 of any of SEQ ID NOs:
• 21-23 and a HC CDR3 of SEQ ID NO:
• 24.